Celldex Therapeutics, Inc.CLDXNASDAQ

Revenue (LTM)

$2M

-78.6% YoY

Net Income (LTM)

$-259M

-63.9% YoY

Free Cash Flow

$-214M

Revenue CAGR (5Y)

-27.4%

Marginsimproving

FCF($0.2B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	5	2↓49.3%	7↑192.0%	7↑2.0%	2↓78.6%
Gross Profit	-49	-80↓64.2%	-111↓39.1%	-157↓40.9%	2↑101.0%
Operating Income	-71	-115↓61.7%	-155↓34.1%	-195↓26.2%	-287↓47.3%
Net Income	-71	-112↓59.3%	-141↓25.9%	-158↓11.6%	-259↓63.9%
EBITDA	-66	-104↓57.7%	-139↓33.4%	-192↓38.0%	-255↓33.1%
EPS Diluted	-1.64	-2.40↓46.3%	-2.92↓21.7%	-2.45↑16.1%	-3.90↓59.2%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	39	29↓24.8%	35↑18.3%	28↓18.6%	29↑1.8%
Total Current Assets	411	318↓22.7%	432↑35.9%	747↑73.1%	535↓28.4%
Total Assets	445	353↓20.7%	466↑32.0%	792↑70.2%	583↓26.4%
Total Current Liabilities	17	19↑12.6%	31↑67.2%	40↑26.9%	51↑29.1%
Total Liabilities	25	27↑5.4%	36↑37.4%	45↑24.4%	56↑23.1%
Total Equity	419	326↓22.2%	429↑31.6%	747↑74.1%	527↓29.4%
Total Debt	3	4↑32.6%	3↓37.0%	4↑50.0%	2↓38.7%
Net Debt	-36	-25↑29.7%	-32↓27.1%	-25↑23.9%	-27↓8.1%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-61	-104↓70.3%	-107↓3.4%	-158↓47.1%	-211↓33.7%
Capital Expenditure	-1	-2↓46.4%	-2↑0.5%	-2↓5.6%	-3↓41.4%
Free Cash Flow	-62	-106↓69.8%	-109↓3.4%	-160↓46.4%	-214↓33.8%
Stock-Based Comp	9	0	24	34↑43.3%	36↑5.8%
Net Change in Cash	-5	-10↓107.0%	5↑155.4%	-6↓219.9%	1↑108.0%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance